Targeting EGFR Signaling Offers a Promising Path for Airway Mucus Hypersecretion
· newswise.com · popularity 14/100 · 0 similar stories today · Chronic Conditions (Health & Life Sciences)
Read the original at newswise.com →
Summary
A new review highlights the epidermal growth factor receptor (EGFR) signaling pathway as a central control point for airway mucus hypersecretion and assesses drugs designed to block it. Excessive mucus production is a shared feature of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and acute respiratory infections, and it is linked to worse lung function and higher mortality. The review synthesizes mechanistic evidence showing how EGFR activation drives goblet cell hyperplasia (GCH) and mucin gene expression, and it evaluates monoclonal antibodies (MABs), tyrosine kinase inhibitors (TKIs), and experimental nanoparticle strategies. Its central message is that EGFR-directed therapy could move mucus management beyond symptomatic relief, although safety and airway selectivity remain critical barriers.
Found in: Newswise. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 24.